Younger Patients With HER2+ Breast Cancer May Benefit from Surgery First
Those aged 18 to 40 years with invasive, HER2-positive breast cancer showed a survival benefit from upfront surgery over neoadjuvant chemotherapy.
Those aged 18 to 40 years with invasive, HER2-positive breast cancer showed a survival benefit from upfront surgery over neoadjuvant chemotherapy.
This inaugural report provides an overview of cancer occurrence, risk factors, and screening for disaggregated Asian American, Native Hawaiian and other Pacific Islander groups in…
In 2022, the European Society for Medical Oncology (ESMO) guideline recommended the adoption of electronic patient-reported outcomes measures (ePROMs)…
Welcome to our Elsevier’s Oncology Journal Network Highlights page
Enrique Grande, MD, PhD, MD Anderson Cancer Centre Madrid, Madrid, Spain, discusses the implications of the findings from the EV-302 trial (NCT04223856) of enfortumab vedotin,…
Open access journal of the Ferrata-Storti Foundation, a no profit organization
Topline findings with the next-generation ColoAlert® test demonstrated 92% sensitivity and 90% specificity rates for colorectal cancer detection.
Relapsed or refractory acute myeloid leukemia (AML) has an extremely poor prognosis because of intrinsic chemotherapy resistance and high rates of relapse,
Prostate Cancer UK has today announced details of a £42 million screening trial, which aims to find the best way to screen men for prostate…
This article evaluates the clinical outcomes of etoposide and cytarabine consolidation chemotherapy following high-dose methotrexate-based induction chemot
This cohort study evaluates the association between bilateral oophorectomy and all-cause mortality among women with BRCA1 or BRCA2 sequence variations.